ReviewDiabetologia2016
Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease.
Review in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- A Phase IIb Randomized Controlled Trial Investigating the Effects of Tocotrienol-Rich Vitamin E on Diabetic Kidney Disease.Nutrients · 2021Trial
- Advances regarding the mechanism of endoplasmic reticulum stress in diabetic kidney disease and pharmacological interventions (Review).Molecular medicine reports · 2026Review
- In silico prediction of optimal multifactorial intervention in chronic kidney disease.Journal of translational medicine · 2025Article
- Serum angiopoietin-2: a promising biomarker for early diabetic kidney disease in children and adolescents with type 1 diabetes.European journal of pediatrics · 2024Article
- A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes.Nature communications · 2024Article
- Biomarkers and signaling pathways of diabetic nephropathy and peripheral neuropathy: possible therapeutic intervention of rutin and quercetin.Diabetology international · 2024Review
- Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus.International journal of molecular sciences · 2024Article
- Urine Peptidome Analysis Identifies Common and Stage-Specific Markers in Early Versus Advanced CKD.Proteomes · 2023Article
- Endoplasmic reticulum stress in diabetic kidney disease: adaptation and apoptosis after three UPR pathways.Apoptosis : an international journal on programmed cell death · 2023Review
- Novel Biomarkers of Diabetic Kidney Disease.Biomolecules · 2023Review
- Antidiabetic effects ofFrontiers in pharmacology · 2023Article
- Article
- Mass spectrometry-based proteomics identify novel serum osteoarthritis biomarkers.Arthritis research & therapy · 2022Article
- Curcuminoid supplementation in canine diabetic mellitus and its complications using proteomic analysis.Frontiers in veterinary science · 2022Article
- Stratification of diabetic kidney diseasesFrontiers in endocrinology · 2022Article
- Current updates on protein as biomarkers for diabetic kidney disease: a systematic review.Therapeutic advances in endocrinology and metabolism · 2021Review
- Importance of Identifying Novel Biomarkers of Microvascular Damage in Type 1 Diabetes.Molecular diagnosis & therapy · 2020Review
- Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.Upsala journal of medical sciences · 2020Article
- Urinary peptidomics and bioinformatics for the detection of diabetic kidney disease.Scientific reports · 2020Article
- Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has resulted in multiple new findings of potential proteomic biomarkers of diabetic kidney disease (DKD). Many of these biomarkers reflect an important role in the (patho)physiology and biological processes of DKD. Situations in which proteomics could be applied in clinical practice include the identification of individuals at risk of progressive kidney disease and those who would respond well to treatment, in order to tailor therapy for those at highest risk. However, while many proteomic biomarkers have been discovered, and even found to be predictive, most lack rigorous external validation in sufficiently powered studies with renal endpoints. Moreover, studies assessing short-term changes in the proteome for therapy-monitoring purposes are lacking. Collaborations between academia and industry and enhanced interactions with regulatory agencies are needed to design new, sufficiently powered studies to implement proteomics in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.